AzTrials
AzTrials

SchizophreniaMIDASNCT03627377

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness

A study testing Multi-component Intervention for Diabetes in Adults with Serious Mental Illness in people with Schizophrenia and Obesity, run by University of California, San Diego at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Schizophrenia, Obesity, Diabetes
What is being tested?
Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Could I receive a placebo?
No, everyone receives an active treatment
How many people
210 participants
Where
1 siteUnited States
Study dates
28 Dec 2018to 31 May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Residential Care Facilities (RCFs):
  • Licensed by California Division of Social Services' Community Care Licensing
  • Serves only individuals with SMI
  • Has >15 residents currently living in the facility
  • Willing to participate
  • Staff Participants:
Show all 14Show fewer
  • Age >21 years
  • Fluent in English
  • Written informed consent to participate
  • Age 18 - 65 years
  • Chart diagnosis of an SMI, mainly schizophrenia, schizoaffective disorder, or bipolar disorder
  • Current treatment with antipsychotics
  • Fluent in English
  • Written informed consent to participate in this study

Who cannot join

  • Plans to leave the RCF during the next year.
  • Resident Participants:
  • Chart diagnosis of dementia or intellectual disability disorder
  • Active substance abuse (non-tobacco)
  • Medical problems that interfere with ability to complete assessments and intervention

Trial locations and contacts

1 site in 1 country.

Dilip V Jeste, MD contact

(858) 534-4020

djeste@ucsd.edu

Danielle K Glorioso, LCSW contact

(858) 246-0767

dglorioso@ucsd.edu

United States1 site, 1 recruiting
  • University of California, San Diego Division of Geriatric Psychiatry

    La Jolla, California, 92093

    Danielle K Glorioso, LCSW, 858-246-0767, dglorioso@ucsd.edu

    Cynthia Ibarra, MA, (858) 822-6005, cyibarra@ucsd.edu

    Recruiting

Other trials in United States

About this study

Official title: Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population. The goals of the proposed study are to implement a multimodal lifestyle intervention to reduce that risk in these individuals living in residential care facilities, a common housing modality for people with serious mental illnesses. If successful, this intervention will lead to reduction in excess medical comorbidity and mortality in persons with serious mental illnesses.

Read the detailed description

Serious mental illnesses (SMI), including schizophrenia, bipolar disorder, and schizoaffective disorder, are associated with increased medical comorbidity and premature mortality from diabetes and cardiovascular disease. Unhealthy lifestyles, including energy-dense (obesogenic) diet, sedentary behavior, and cigarette smoking are important risk factors for diabetes and accelerated biological aging. All of these risk factors are potentially modifiable. There is considerable literature documenting the effectiveness of strategies to prevent and manage diabetes in the general population; yet, these interventions are rarely offered to people with SMI. Residential Care Facilities (RCFs), called Board-and-Care Homes in California, are a common housing modality for patients with SMI; they provide a venue that can maximize efficiency and sustainability of a lifestyle intervention. The goals of the proposed four-year study are to tailor a multi-component intervention to this high-risk group. The study will be a hybrid effectiveness-implementation (Hybrid Type 1) trial of a Multi-component Intervention for Diabetes risk reduction in Adults with SMI (MIDAS) in licensed RCFs in San Diego county. As a Hybrid Type 1 study, the primary emphasis will be on determining the effectiveness of the intervention to achieve desired health outcomes while also systematically collecting data on its implementation within RCFs that will inform implementation strategy refinement. Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction. The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period. Our investigators will train RCF staff (especially the Activity Director and cook) to increase physical activity and reduce smoking, and to implement healthful dietary modifications among the residents, using evidence-based interventions. During the intervention phase, the RCF Activity Director will conduct twice-weekly manualized group sessions on education about diabetes, nutrition, exercise, and smoking cessation/reduction, to deliver a multi-component group intervention. We will also explore if there are improvements in blood-based research biomarkers of insulin resistance and inflammation in the RCF residents with SMI. This project is responsive to RFA-MH-17-608, and related to NIMH Strategic Objective #3.3B: testing interventions for effectiveness in community practice settings. If successful, MIDAS will be sustained and disseminated, and would lead to reduction in excess medical comorbidity and mortality associated with SMI.

Being tested
Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Keywords
Schizophrenia, Serious mental illness, Obesity, Diabetes, Lifestyle Risk Reduction
Medical subject headings
Schizophrenia, Obesity, Diabetes Mellitus, Risk Reduction Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multi-component Intervention for Diabetes in Adults with Serious Mental IllnessBehavioural

    Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.

Study groups in NCT03627377
Study groupRoleWhat they receive
Control PhaseNo intervention3-month initial control phase (no intervention, month 1-3)
Intervention PhaseExperimental6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
Receives: Behavioral: Multi-component Intervention for Diabetes in Adults with Serious Mental Illness

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body Mass Index (BMI in kg/m^2)

    Change in Body Mass Index

    Measured: Baseline to 9 months and sustained at 15 months

  2. Waist Circumference

    Change in Waist Circumference

    Measured: Baseline to 9 months and sustained at 15 months

  3. Fasting Glucose

    Change in Fasting Glucose

    Measured: Baseline to 9 months and sustained at 15 months

  4. Hemoglobin A1c or HbA1c

    Change in Hemoglobin A1c or HbA1c

    Measured: Baseline to 9 months and sustained at 15 months

Secondary outcomes (5)
  1. Diet/Nutrition - Plasma Carotenoid Levels

    Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.Nutrition Data Systems for REsearch (NDS-R) Protocol

    Measured: Baseline to 9 months and sustained at 15 months

  2. Diet/Nutrition - Serum Lipid Levels

    Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.

    Measured: Baseline to 9 months and sustained at 15 months

  3. Objective Measure of Physical Activity

    For 7 days during each assessment period, participants will wear the GT3X+ Actigraph, which measures movement and intensity of activity, and has good validation with VO2max. It provides estimates of activity by seconds, that can be categorized into minutes spent in sedentary, light, moderate, and vigorous activity using calibration thresholds.

    Measured: Baseline to 9 months and sustained at 15 months

  4. Smoking - Expired Breath Carbon Monoxide (CO) Levels

    Change in Smoking - Objective Measure of Cigarette Use: Expired Breath Carbon Monoxide (CO) level (parts per million) is measured with a handheld device. CO monitoring is used primarily as a check on recent smoking, though it has also been used to indicate reductions in smoking.

    Measured: Baseline to 9 months and sustained at 15 months

  5. Smoking - Change in Smoking through Recall

    Change in Smoking - Quantity and frequency of cigarette use for the prior week using a timeline followback procedure. Smoking reduction calculated by % change in average cigarettes/day across assessments.

    Measured: Baseline to 9 months and sustained at 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2018
  2. Study start28 Dec 2018
  3. Primary completion31 May 2022 (estimated)
  4. Study completion31 May 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Sequential
Model description
The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period.
Masking
None (open label)
Enrolment
210 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03627377
Sponsor's protocol ID
MH15127
Acronym
MIDAS
Status last verified
Sep 2021
First submitted
5 Jul 2018
Last updated
17 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Multi-component Intervention for Diabetes in Adults with Serious Mental Illness in people with Schizophrenia and Obesity, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dilip V Jeste, MD ((858) 534-4020, djeste@ucsd.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body Mass Index (BMI in kg/m^2) (time frame: Baseline to 9 months and sustained at 15 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in